J-AXEL: nab-paclitaxel at least equal to docetaxel in pretreated NSCLC

Various advantages have been described for nab-paclitaxel, the albumin-bound, solvent-free, nanoparticle formulation of paclitaxel [1-3]. Phase II data showed favorable results in patients with pretreated advanced NSCLC who obtained an ORR of 32 % and median PFS of 5 months [4]. Therefore, the randomized, phase III study reported by Nakamura et al. compared nab-paclitaxel 100 mg/m2 on days 1, 8 and 15 three-weekly with docetaxel 60 mg/m2 every three weeks in patients with stage IIIB/IV or recurrent NSCLC previously treated with cytotoxic chemotherapy [5]. The analysis aimed to demonstrate non-inferiority of nab-paclitaxel with respect to OS. Both arms included approximately 250 patients. 

Significant PFS and ORR benefits

Non-inferiority of nab-paclitaxel in terms of OS was confirmed with the protocol-specified margin of 1.25 in the intent-to-treat population (HR, 0.85; 95.2 % CI, 0.68–1.070). Median OS amounted to 16.2 and 13.6 months with nab-paclitaxel and docetaxel, respectively. As specified by the protocol, superiority of nab-paclitaxel over docetaxel for OS was tested after non-inferiority had been shown. However, nab-paclitaxel did not significantly improve survival, although this was the case for both PFS and ORR. Median PFS was 4.2 vs. 3.4 months with nab-paclitaxel and docetaxel (HR, 0.76; p = 0.0042). In the total group (n = 459), 29.9 % vs. 15.4 % of patients responded to treatment (p = 0.0002; Figure). For the patients with squamous histology (n = 94), this was 30.4 % vs. 10.4 % (p = 0.0207), and for those with non-squamous NSCLC (n = 365), 29.7 % vs. 16.7 % (p = 0.0042). The results for both PFS and OS favored nab-paclitaxel across various subgroups pertaining to age, sex, ECOG performance status, histology, smoking status, disease stage, EGFR mutation status, and pretreatment. 

Hematologic toxicity with docetaxel and neuropathy with nab-paclitaxel 

Among AEs, leukopenia and neutropenia occurred significantly more often with docetaxel than with nab-paclitaxel (p < 0.0001 for both comparisons); correspondingly, docetaxel conferred a significantly higher incidence of febrile neutropenia (22.1 % vs 2.0 %). On the other hand, peripheral ­sensory neuropathy was more frequent with nab-paclitaxel (55.5 % vs. 20.1 %, p < 0.0001). The authors stressed in their summary that nab-paclitaxel should be considered a standard option for previously treated patients with advanced NSCLC. 

Figure: Objective responses rates achieved with nab-paclitaxel vs. docetaxel in the ITT population and according to histology

Figure: Objective responses rates achieved with nab-paclitaxel vs. docetaxel in the ITT population and according to histology

REFERENCES

  1. Desai N et al., Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12(4): 1317-1324
  2. Sasaki Y et al., Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci 2014; 105(7): 812-817
  3. Gradishar WJ et al., Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27(22): 3611-3619
  4. Sakata S et al., Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. Lung Cancer 2016; 99: 41-45
  5. Nakamura A et al., Phase III study comparing nab-paclitaxel with docetaxel in patients with previously treated advanced non-small cell lung cancer_J-AXEL. WCLC 2020, OA03.05

© 2020 Springer-Verlag GmbH, Impressum

More posts

Nivolumab as a new option in patients with relapsed malignant mesothelioma

Until recently, no randomized phase III trials have demonstrated OS improvement in patients with relapsed malignant mesothelioma. PD-1 inhibition with single-agent nivolumab has shown activity in three phase II studies, one of which led to the approval of nivolumab in Japan.

Interview: Lung cancer screening: hurdles in daily routine and in the research laboratory

All of us agree that LDCT is effective and should be widely implemented. I would say that cost and awareness are the two major issues that are impeding the implementation of LDCT all over the world. Cost-effectiveness of LDCT has been demonstrated by many publications; and there are even other arguments in favor of the cost-effectiveness of this technology.

What is new in SCLC?

A novel approach for targeting lung tumors with small-cell histology consists in the inhibition of transactivated transcription, as small-cell lung cancer (SCLC) has been found to be a transcription-addicted malignancy. Rudin et al. defined four molecular SCLC subtypes according to their differential expression of four key transcription regulators.

Interview: Antibody-drug conjugates: the age of almost unlimited possibilities has just begun

Antibody-drug conjugates have opened up an entirely new paradigm. Targeted therapy requires specific mutations, and immunotherapy only works if the tumor expresses neoantigens or is essentially able to respond to these agents. As we know, these two approaches do not work forever, not every patient responds to them, and certainly not every patient has a targetable mutation.

Specific treatment approaches in the EGFR-mutated setting

EGFR exon 20 insertion mutations are found in approximately 5 % to 12 % of EGFR-mutated NSCLC tumors, i.e., in 2 % of all NSCLC cases. They represent the third most common EGFR mutation after L858R and exon 19 deletion. However, EGFR TKIs cannot be used to treat lung cancer with exon 20 insertions as they are insensitive to these drugs due to steric hindrance at the TKI-binding site.